MRVI Investors Have Opportunity to Lead Maravai LifeSciences Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Maravai LifeSciences Holdings, Inc. due to allegations of violations of federal securities laws, particularly concerning revenue recognition and internal controls [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Maravai LifeSciences between August 7, 2024, and February 24, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Maravai, with a deadline of May 5, 2025, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Maravai and its executives made false or misleading statements regarding the company's financial reporting and internal controls [4]. Group 2: Financial Reporting Issues - On February 25, 2025, Maravai announced a postponement of its fiscal 2024 earnings release due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [5]. - The company identified a material weakness in its internal controls over revenue recognition, which contributed to the inaccuracies in financial reporting [5]. - Following the announcement, Maravai's share price fell by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, amid unusually heavy trading volume [5]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].